Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Data Update: Innovative ART Strategies

Michelle S. Cespedes, MD, MS, reviews new data on emerging agents such as islatravir and lenacapavir.
W. David Hardy, MD
Program Director
Michelle S. Cespedes, MD, MS
Gregory Huhn, MD, MPHTM
David A. Wohl, MD
Released: October 22, 2020

Information on this Educational Activity

Program Director

W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine

Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California

W. David Hardy, MD, has disclosed that he has received consulting fees from Enochian Biosciences, Gilead Sciences, Merck, and ViiV/GlaxoSmithKline.

Faculty

Michelle S. Cespedes, MD, MS

Associate Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at Mount Sinai
Attending Physician
Mount Sinai Medical Center
New York, New York

Michelle S. Cespedes, MD, MS, has disclosed that she has received consulting fees from Gilead Sciences and ViiV Healthcare.
Gregory Huhn, MD, MPHTM

Associate Professor
Department of Infectious Diseases
Rush University Medical Center
Senior Director of HIV Services
Department of Infectious Diseases
Cook County Health
Chicago, Illinois

Gregory Huhn, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences, Janssen, Lilly, Proteus, and ViiV; consulting fees from Lilly and Janssen; and has served on advisory boards or panels for Gilead Sciences, Janssen, and ViiV.
David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader,  AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director, HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences, Merck, and ViiV and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Scientific Director

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, clinical pharmacists, nurses and other healthcare providers who care for patients with HIV.

Goal

The goal of this activity is to enhance clinicians' competence in addressing the most important and most current challenges in HIV disease management by providing a tightly focused update on recent advances and key issues encountered in the clinic.

Program Medium

This program has been made available online.

Related Content

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Jean-Michel Molina, MD, PhD Cristina Mussini, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

From Dr Gregory Huhn and Clinical Care Options (CCO), slides on new data from fall 2021 HIV conferences expand our understanding of adverse events with specific ART regimens

Released: December 22, 2021

From Dr Gregory Huhn and Clinical Care Options (CCO), expert discussion on how new data from fall 2021 HIV conferences expand our understanding of adverse events with specific ART regimens

Gregory Huhn, MD, MPHTM Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: December 22, 2021 Expired: December 21, 2022

Selecciones de datos sobre el VIH realizadas por expertos extraídos de EACS 2021, incluida la TAR actual y la experimental y la eficacia de la vacuna contra la COVID-19 y su impacto en las personas con VIH.

Tristan J. Barber, MA, MD, FRCP Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Jürgen K. Rockstroh, MD Released: December 17, 2021

Video Chapters


Provided by University of South Florida

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings